knowledge -WSS

knowledge

author：fashion 2025-08-25 08:46:42 - browse：7349

LIONEL BONAVENTURE/AFP via Getty Images

On Tuesday, Duke Health and Microsoft announced a five-year partnership that will support artificial intelligence applications in medicine, with a focus on building out infrastructure such as cloud-based data platforms.

Duke Health and Microsoft are both members of the Coalition for Health AI, a group of companies, hospitals, and federal agencies that formed late last year to develop guidelines for the responsible use of AI in medicine. “We have all these operational things we want to do in the health system, and we also have an academic interest in trustworthy AI,” said Jeffrey Ferranti, senior vice president and chief digital officer of Duke Health.

So Duke and Microsoft will collaborate within the newly-established Duke Health AI Innovation Lab and Center of Excellence, where researchers can develop new AI tools “while paying attention to some of the things that could go wrong,” said Ferranti. “Because there are a lot of things that can go wrong as we introduce new technology.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： How AI can help patients find reliable information about doctors

hotspot

WSS

NVIDIA and Google execs on the future of AI and drug discovery

Smaller biotechs seek to piggyback on weight loss drug boom

Cytokinetics CEO stresses company can launch heart drug on its own

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Health tech investors get more selective as pandemic boom fades

leisure time

knowledge

entertainment

Duchenne breakthrough therapy leaves behind pioneering families

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Bright Health sells Medicare Advantage business to Molina

STAT Readout: Friday, Oct. 20 biotech updates

Anesthesiologist group: stop taking Ozempic before surgery

When prostate cancer spreads, where it goes matters

Novavax promises a turnaround & Lilly roils the obesity market

It's time to retire 'poor historian' from clinicians' vocabularies

BioMarin wins approval for gene therapy to treat hemophilia A

STAT Summit: The economic case for universal basic health care

focus

Roivant's CEO is a star, but biotech's black hole persists

Questions loom on AstraZeneca cancer drug as safety concerns ebb

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Venture capitalist Bob Kocher on the state of digital health

hotspot

explore

hotspot

explore